Hologic, Inc.: peers
Hologic, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Hologic, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Hologic, Inc.base HOLX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Glaukos Corporation GKOS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Baxter International Inc. BAX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Repligen Corporation RGEN · 🇺🇸 US Percentile in Healthcare Percentile in USA | The Cooper Companies, Inc. COO · 🇺🇸 US Percentile in Healthcare Percentile in USA | West Pharmaceutical Services, Inc. WST · 🇺🇸 US Percentile in Healthcare Percentile in USA | ResMed Inc. RMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Merit Medical Systems, Inc. MMSI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $16.9 Blast known, Mar 8, 2026 · Market dataLast known value: no current one3rd of 8 | $14.4 BOct 30, 2026 · Market data4th of 8 | $12.9 BOct 28, 2026 · Market data5th of 8 | $11.5 BOct 27, 2026 · Market data6th of 8 | $11.3 BOct 29, 2026 · Market data7th of 8 | $27.1 BOct 21, 2026 · Market data2nd of 8 | $35.3 BOct 28, 2026 · Market data1st of 8 | $5.6 BOct 26, 2026 · Market data8th of 8 | $13.6 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $4.1 BFY2025 · SEC3rd of 8 | $507 MFY2025 · SEC8th of 8 | $11.2 BFY2025 · SEC1st of 8 | $738 MFY2025 · SEC7th of 8 | $4.1 BFY2025 · SEC4th of 8 | $3.1 BFY2025 · SEC5th of 8 | $5.7 BFY2026 · SEC2nd of 8 | $1.5 BFY2025 · SEC6th of 8 | $3.6 B8 ranked |
| Net income (Higher is better) | $566 MFY2025 · SEC2nd of 8 | $-188 MFY2025 · SEC7th of 8 | $-957 MFY2025 · SEC8th of 8 | $49 MFY2025 · SEC6th of 8 | $375 MFY2025 · SEC4th of 8 | $494 MFY2025 · SEC3rd of 8 | $1.5 BFY2026 · SEC1st of 8 | $128 MFY2025 · SEC5th of 8 | $252 M8 ranked |
| Employees (Better neither way: ranked highest first) | 6,944As on 2022 · Profile4th of 8 | 1,094December 31, 2025 · Profile7th of 8 | 37,500December 31, 2025 · Profile1st of 8 | 2,000December 31, 2025 · Profile6th of 8 | 500October 31, 2025 · Profile8th of 8 | 10,800December 31, 2025 · Profile3rd of 8 | 11,370June 30, 2026 · Profile2nd of 8 | 6,446As on 2021 · Profile5th of 8 | 6,6958 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | —— | —— | +6.6%30 days to Oct 26, 2026 · Market dataonly one with it | +6.6%— |
| Revenue growth (Higher is better) | +1.7%FY2025 · SEC8th of 830th34th | +32.3%FY2025 · SEC1st of 878th87th | +5.7%FY2025 · SEC6th of 839th48th | +16.4%FY2025 · SEC2nd of 862nd73rd | +5.1%FY2025 · SEC7th of 837th46th | +6.3%FY2025 · SEC5th of 841st49th | +9.8%FY2026 · SEC4th of 849th61st | +11.8%FY2025 · SEC3rd of 854th65th | +8.1%8 ranked |
| Revenue growth, 3 years a year (Higher is better) | -5.5%FY2025 · SEC8th of 816th17th | +21.5%FY2025 · SEC1st of 874th86th | +3.8%FY2025 · SEC5th of 838th48th | -2.7%FY2025 · SEC7th of 820th24th | +7.3%FY2025 · SEC4th of 847th61st | +2.1%FY2025 · SEC6th of 833rd41st | +10.2%FY2026 · SEC2nd of 854th70th | +9.6%FY2025 · SEC3rd of 852nd68th | +5.6%8 ranked |
| Earnings per share growth (Higher is better) | -25.0%FY2025 · SEC5th of 519th19th | ———— | ———— | ———— | -4.6%FY2025 · SEC4th of 531st33rd | +1.5%FY2025 · SEC3rd of 540th40th | +9.7%FY2026 · SEC1st of 551st50th | +4.9%FY2025 · SEC2nd of 544th44th | +1.5%5 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 51.6%FY2025 · SEC5th of 838th65th | 55.7%FY2025 · SEC3rd of 845th69th | 30.1%FY2025 · SEC8th of 816th35th | 52.3%FY2025 · SEC4th of 839th66th | 65.5%FY2025 · SEC1st of 861st79th | 35.9%FY2025 · SEC7th of 822nd44th | 61.1%FY2026 · SEC2nd of 854th75th | 48.7%FY2025 · SEC6th of 834th62nd | 52.0%8 ranked |
| Operating margin (Higher is better) | 17.4%FY2025 · SEC3rd of 885th82nd | -39.3%FY2025 · SEC8th of 834th17th | -2.7%FY2025 · SEC7th of 854th35th | 7.5%FY2025 · SEC6th of 868th62nd | 16.7%FY2025 · SEC4th of 884th81st | 19.0%FY2025 · SEC2nd of 887th84th | 33.4%FY2026 · SEC1st of 896th95th | 12.2%FY2025 · SEC5th of 876th73rd | 14.4%8 ranked |
| Net margin (Higher is better) | 13.8%FY2025 · SEC3rd of 884th82nd | -37.0%FY2025 · SEC8th of 835th17th | -8.5%FY2025 · SEC7th of 849th28th | 6.6%FY2025 · SEC6th of 873rd66th | 9.2%FY2025 · SEC4th of 878th73rd | 16.1%FY2025 · SEC2nd of 886th85th | 26.9%FY2026 · SEC1st of 893rd93rd | 8.5%FY2025 · SEC5th of 876th71st | 8.8%8 ranked |
| Free cash flow margin (Higher is better) | 24.4%FY2025 · SEC2nd of 893rd92nd | -4.4%FY2025 · SEC8th of 845th26th | 3.0%FY2025 · SEC7th of 858th45th | 12.7%FY2025 · SEC5th of 877th76th | 10.6%FY2025 · SEC6th of 873rd71st | 15.3%FY2025 · SEC3rd of 881st81st | 29.2%FY2026 · SEC1st of 896th95th | 14.2%FY2025 · SEC4th of 880th79th | 13.5%8 ranked |
| Return on equity (Higher is better) | 11.1%FY2025 · SEC3rd of 883rd68th | -26.4%FY2025 · SEC8th of 856th25th | -14.6%FY2025 · SEC7th of 863rd30th | 2.4%FY2025 · SEC6th of 874th46th | 4.6%FY2025 · SEC5th of 876th50th | 16.9%FY2025 · SEC2nd of 889th81st | 24.3%FY2026 · SEC1st of 893rd88th | 8.7%FY2025 · SEC4th of 879th60th | 6.6%8 ranked |
| Return on invested capital (Higher is better) | 10.7%FY2025 · SEC3rd of 648th50th | ———— | ———— | 2.3%FY2025 · SEC6th of 610th5th | 4.3%FY2025 · SEC5th of 616th13th | 18.7%FY2025 · SEC2nd of 677th76th | 27.4%FY2026 · SEC1st of 686th86th | 7.7%FY2025 · SEC4th of 628th32nd | 9.2%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 19.8×price Oct 29, 2026 · Market data4th of 432nd52nd | 42.4×price Oct 21, 2026 · Market data1st of 466th83rd | 22.1×price Oct 28, 2026 · Market data3rd of 436th58th | 34.9×price Oct 26, 2026 · Market data2nd of 454th78th | 28.5×4 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | 20.8×price Oct 30, 2026 · Market data1st of 784th94th | 1.1×price Oct 28, 2026 · Market data7th of 719th32nd | 14.3×price Oct 27, 2026 · Market data2nd of 779th92nd | 2.7×price Oct 29, 2026 · Market data6th of 740th56th | 8.0×price Oct 21, 2026 · Market data3rd of 769th86th | 6.2×price Oct 28, 2026 · Market data4th of 761st81st | 3.5×price Oct 26, 2026 · Market data5th of 748th66th | 6.2×7 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 21.9×price Oct 30, 2026 · Market data1st of 793rd96th | 2.1×price Oct 28, 2026 · Market data6th of 739th49th | 5.5×price Oct 27, 2026 · Market data3rd of 770th78th | 1.4×price Oct 29, 2026 · Market data7th of 726th33rd | 8.5×price Oct 21, 2026 · Market data2nd of 781st87th | 5.4×price Oct 28, 2026 · Market data4th of 769th77th | 3.5×price Oct 26, 2026 · Market data5th of 756th67th | 5.4×7 ranked |
| Free cash flow yield (Higher is better) | ———— | -0.2%price Oct 30, 2026 · Market data7th of 768th37th | 2.6%price Oct 28, 2026 · Market data4th of 778th50th | 0.8%price Oct 27, 2026 · Market data6th of 772nd40th | 3.8%price Oct 29, 2026 · Market data3rd of 782nd59th | 1.7%price Oct 21, 2026 · Market data5th of 775th45th | 4.7%price Oct 28, 2026 · Market data1st of 786th65th | 3.9%price Oct 26, 2026 · Market data2nd of 782nd59th | 2.6%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.5×FY2025 · SEC6th of 753rd44th | ———— | 1.5×FY2025 · SEC7th of 786th80th | 0.3×FY2025 · SEC3rd of 736th27th | 0.3×FY2025 · SEC4th of 739th30th | 0.1×FY2025 · SEC1st of 715th11th | 0.1×FY2026 · SEC1st of 715th11th | 0.5×FY2025 · SEC5th of 752nd41st | 0.3×7 ranked |
| Net debt to EBITDA (Lower is better) | 0.5×FY2025 · SEC4th of 733rd27th | ———— | 11.1×FY2025 · SEC7th of 795th95th | -0.2×FY2025 · SEC3rd of 723rd15th | 2.2×FY2025 · SEC6th of 755th52nd | -0.8×FY2025 · SEC1st of 714th9th | -0.5×FY2026 · SEC2nd of 717th11th | 0.9×FY2025 · SEC5th of 739th33rd | 0.5×7 ranked |
| Interest cover (Higher is better) | ———— | ———— | -1.1×FY2025 · SEC3rd of 366th42nd | 2.4×FY2025 · SEC2nd of 381st62nd | ———— | 38.7×FY2025 · SEC1st of 398th95th | ———— | ———— | 2.4×3 ranked |
| Piotroski F-score (Higher is better) | 6 of 9FY2025 · SEC5th of 7 | —— | 4 of 9FY2025 · SEC7th of 7 | 7 of 9FY2025 · SEC1st of 7 | 6 of 9FY2025 · SEC5th of 7 | 7 of 9FY2025 · SEC1st of 7 | 7 of 9FY2026 · SEC1st of 7 | 7 of 9FY2025 · SEC1st of 7 | 7.0 of 97 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 11 of 18FY2025 · Scorecard5th of 8 | 6 of 20FY2025 · Scorecard8th of 8 | 10 of 28FY2025 · Scorecard7th of 8 | 11 of 26FY2025 · Scorecard6th of 8 | 20 of 27FY2025 · Scorecard2nd of 8 | 20 of 30FY2025 · Scorecard4th of 8 | 24 of 29FY2026 · Scorecard1st of 8 | 17 of 24FY2025 · Scorecard3rd of 8 | 64% passed8 ranked |
| Valuation checks (Higher is better) | —— | 0 of 5FY2025 · Scorecard5th of 7 | 2 of 6FY2025 · Scorecard2nd of 7 | 0 of 6FY2025 · Scorecard5th of 7 | 4 of 6FY2025 · Scorecard1st of 7 | 0 of 6FY2025 · Scorecard5th of 7 | 2 of 6FY2026 · Scorecard2nd of 7 | 1 of 6FY2025 · Scorecard4th of 7 | 17% passed7 ranked |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecard8th of 8 | 4 of 6FY2025 · Scorecard4th of 8 | 2 of 6FY2025 · Scorecard7th of 8 | 3 of 6FY2025 · Scorecard6th of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 4 of 6FY2025 · Scorecard4th of 8 | 6 of 6FY2026 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 67% passed8 ranked |
| Profitability checks (Higher is better) | 4 of 6FY2025 · Scorecard3rd of 8 | 0 of 5FY2025 · Scorecard8th of 8 | 1 of 5FY2025 · Scorecard7th of 8 | 2 of 6FY2025 · Scorecard6th of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 5 of 6FY2025 · Scorecard2nd of 8 | 6 of 6FY2026 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 67% passed8 ranked |
| Financial health checks (Higher is better) | 4 of 4FY2025 · Scorecard1st of 8 | 2 of 3FY2025 · Scorecard7th of 8 | 3 of 6FY2025 · Scorecard8th of 8 | 5 of 6FY2025 · Scorecard6th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 5 of 5FY2026 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 100% passed8 ranked |
| Shareholder returns checks (Higher is better) | 2 of 2FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard8th of 8 | 2 of 5FY2025 · Scorecard7th of 8 | 1 of 2FY2025 · Scorecard5th of 8 | 2 of 4FY2025 · Scorecard5th of 8 | 5 of 6FY2025 · Scorecard3rd of 8 | 5 of 6FY2026 · Scorecard3rd of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 67% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 96.3%2026-Q1 · 13F7th of 8 | 100.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 100.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 110.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 103.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 99.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 65.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 104.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 100.4%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 6982026-Q1 · 13F4th of 8 | 4222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 7382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 5242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 6462026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 8782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 8842026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 4242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 6728 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +0.6 pp2026-Q1 against 2025-Q4 · 13F7th of 8 | +4.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +5.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +1.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | +2.8 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | -0.4 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +2.4 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | +2.6 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | 2.7%FY2025 · SEC1st of 485th63rd | ———— | 0.0%FY2025 · SEC4th of 46th2nd | 0.2%FY2025 · SEC3rd of 420th9th | 1.0%FY2026 · SEC2nd of 451st26th | ———— | 0.6%4 ranked |
| Shareholder yield (Higher is better) | ———— | ———— | 2.7%FY2025 · SEC2nd of 557th44th | 0.0%FY2025 · SEC5th of 57th3rd | 2.6%FY2025 · SEC3rd of 554th42nd | 0.7%FY2025 · SEC4th of 527th18th | 3.0%FY2026 · SEC1st of 560th48th | ———— | 2.6%5 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 0.0%FY2025 · SEC3rd of 32nd1st | 12.4%FY2025 · SEC2nd of 328th12th | 22.9%FY2026 · SEC1st of 341st26th | ———— | 12.4%3 ranked |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | $0.52FY2025 · SEC3rd of 3 | —— | —— | $0.86FY2025 · SEC2nd of 3 | $2.40FY2026 · SEC1st of 3 | —— | $0.863 ranked |
| Years of dividend raises (Higher is better) | —— | —— | —— | —— | —— | —— | 12to 2025 · SEConly one with it | —— | 12— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Hologic, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Glaukos Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Baxter International Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Repligen Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; The Cooper Companies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; West Pharmaceutical Services, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ResMed Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merit Medical Systems, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Hologic, Inc. | 17.4%FY2025 | 85th percentile in Healthcaremedian -7.7%, 674 companies | 82nd percentile in USAmedian 3.5%, 2,594 companies |
| Glaukos Corporation | -39.3%FY2025 | 34th percentile in Healthcaremedian -7.7%, 674 companies | 17th percentile in USAmedian 3.5%, 2,594 companies |
| Baxter International Inc. | -2.7%FY2025 | 54th percentile in Healthcaremedian -7.7%, 674 companies | 35th percentile in USAmedian 3.5%, 2,594 companies |
| Repligen Corporation | 7.5%FY2025 | 68th percentile in Healthcaremedian -7.7%, 674 companies | 62nd percentile in USAmedian 3.5%, 2,594 companies |
| The Cooper Companies, Inc. | 16.7%FY2025 | 84th percentile in Healthcaremedian -7.7%, 674 companies | 81st percentile in USAmedian 3.5%, 2,594 companies |
| West Pharmaceutical Services, Inc. | 19.0%FY2025 | 87th percentile in Healthcaremedian -7.7%, 674 companies | 84th percentile in USAmedian 3.5%, 2,594 companies |
| ResMed Inc. | 33.4%FY2026 | 96th percentile in Healthcaremedian -7.7%, 674 companies | 95th percentile in USAmedian 3.5%, 2,594 companies |
| Merit Medical Systems, Inc. | 12.2%FY2025 | 76th percentile in Healthcaremedian -7.7%, 674 companies | 73rd percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Hologic, Inc. | Glaukos Corporation | Baxter International Inc. | Repligen Corporation | The Cooper Companies, Inc. | West Pharmaceutical Services, Inc. | ResMed Inc. | Merit Medical Systems, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — | $5.7 BSEC | — |
| 2025 | $4.1 BSEC3rd | $507 MSEC8th | $11.2 BSEC1st | $738 MSEC7th | $4.1 BSEC4th | $3.1 BSEC5th | $5.1 BSEC2nd | $1.5 BSEC6th |
| 2024 | $4.0 BSEC3rd | $383 MSEC8th | $10.6 BSEC1st | $634 MSEC7th | $3.9 BSEC4th | $2.9 BSEC5th | $4.7 BSEC2nd | $1.4 BSEC6th |
| 2023 | $4.0 BSEC3rd | $315 MSEC8th | $10.4 BSEC1st | $632 MSEC7th | $3.6 BSEC4th | $2.9 BSEC5th | $4.2 BSEC2nd | $1.3 BSEC6th |
| 2022 | $4.9 BSEC2nd | $283 MSEC8th | $10.1 BSEC1st | $802 MSEC7th | $3.3 BSEC4th | $2.9 BSEC5th | $3.6 BSEC3rd | $1.2 BSEC6th |
| 2021 | $5.6 BSEC2nd | $294 MSEC8th | $12.1 BSEC1st | $671 MSEC7th | $2.9 BSEC4th | $2.8 BSEC5th | $3.2 BSEC3rd | $1.1 BSEC6th |
| 2020 | $3.8 BSEC2nd | $225 MSEC8th | $11.7 BSEC1st | $366 MSEC7th | $2.4 BSEC4th | $2.1 BSEC5th | $3.0 BSEC3rd | $964 MSEC6th |
| 2019 | $3.4 BSEC2nd | $237 MSEC8th | $11.4 BSEC1st | $270 MSEC7th | $2.7 BSEC3rd | $1.8 BSEC5th | $2.6 BSEC4th | $995 MSEC6th |
| 2018 | $3.2 BSEC2nd | $181 MSEC8th | $11.1 BSEC1st | $194 MSEC7th | $2.5 BSEC3rd | $1.7 BSEC5th | $2.3 BSEC4th | $883 MSEC6th |
| 2017 | $3.1 BSEC2nd | $159 MSEC7th | $10.6 BSEC1st | $141 MSEC8th | $2.1 BSEC3rd | $1.6 BSEC5th | $2.1 BSEC4th | $728 MSEC6th |
| 2016 | $2.8 BSEC2nd | $114 MSEC7th | $10.2 BSEC1st | $105 MSEC8th | $2.0 BSEC3rd | $1.5 BSEC5th | $1.8 BSEC4th | $604 MSEC6th |
| 2015 | $2.7 BSEC2nd | $72 MSEC8th | $10.0 BSEC1st | $84 MSEC7th | $1.8 BSEC3rd | $1.4 BSEC5th | $1.7 BSEC4th | $542 MSEC6th |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Hologic, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Glaukos CorporationGKOS · 🇺🇸 USASame industry: Medical Instruments · Similar size: $14.4 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14.4 B (Oct 30, 2026) · revenue $507 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Baxter International Inc.BAX · 🇺🇸 USASame industry: Medical Instruments · Similar size: $12.9 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $12.9 B (Oct 28, 2026) · revenue $11.2 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Repligen CorporationRGEN · 🇺🇸 USASame industry: Medical Instruments · Similar size: $11.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $11.5 B (Oct 27, 2026) · revenue $738 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- The Cooper Companies, Inc.COO · 🇺🇸 USASame industry: Medical Instruments · Similar size: $11.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $11.3 B (Oct 29, 2026) · revenue $4.1 B (year to October 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- West Pharmaceutical Services, Inc.WST · 🇺🇸 USASame industry: Medical Instruments · Similar size: $27.1 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $27.1 B (Oct 21, 2026) · revenue $3.1 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- ResMed Inc.RMD · 🇺🇸 USASame industry: Medical Instruments · Similar size: $35.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $35.3 B (Oct 28, 2026) · revenue $5.7 B (year to June 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Merit Medical Systems, Inc.MMSI · 🇺🇸 USASame industry: Medical Instruments · Similar size: $5.6 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.6 B (Oct 26, 2026) · revenue $1.5 B (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)In the group
- Teleflex IncorporatedTFX · 🇺🇸 USASame industry: Medical Instruments · Similar size: $5.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.5 B (Oct 28, 2026) · revenue $2.0 B (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
- Haemonetics CorporationHAE · 🇺🇸 USASame industry: Medical Instruments · Similar size: $5.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.5 B (Oct 28, 2026) · revenue $1.3 B (year to March 2026)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
- Becton, Dickinson and CompanyBDX · 🇺🇸 USASame industry: Medical Instruments · Similar size: $54.0 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $54.0 B (Oct 30, 2026) · revenue $21.8 B (year to September 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
- Masimo CorporationMASI · 🇺🇸 USASame industry: Medical Instruments · Similar size: $9.4 B market cap against $16.9 B · Same country: USAMarket cap $9.4 B (last known, Aug 1, 2026) · revenue $1.5 B (year to January 2026)91 of 100 (industry or sector 50 + size 26 + country 15)+ Add
- iRhythm Technologies, Inc.IRTC · 🇺🇸 USASame industry: Medical Instruments · Similar size: $4.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $4.3 B (Oct 30, 2026) · revenue $747 M (year to December 2025)91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.